
Registering a Medical Device in Africa – Classification, Reliance, and the Readiness Question

Of 44 African countries with medical device laws, 26 have device guidelines, and 22 of those set out registration requirements. Foreign manufacturers typically need a local representative but stay responsible for the device throughout its lifecycle. Devices are self-classified by risk, and the dossier and pathway follow that class. Pathways can be shortened when a trusted regulator has already assessed the product. Reliance mechanisms exist in South Africa, Nigeria, Mozambique, Egypt and Botswana, but local submission requirements still apply. Timelines depend on both regulators and applicants, so manufacturers need early, realistic planning for market entry.
In the second part of our research, we move from the 26 African countries with medical device guidelines, out of the 44 countries identified as having laws covering medical devices, to what these frameworks mean in practice. Having a law is one step; understanding how a product gets registered and reaches the market is another.
We started by exploring four key questions to reveal the state of our registration ecosystem:
What does a company need to register its devices?
How are devices classified?
What does the registration process look like? (technical dossier, registration pathways and timelines)
And where does reliance come in?
Before the product reaches the market, who carries the responsibility?
Across the 26 countries, 22 countries had outlined their registration requirements, and appointing a local representative was a recurring requirement for foreign manufacturers.
So, who can be the local representative?
The title keeps changing from border to border, but the purpose is the same: giving the regulator a designated local contact. In Nigeria, an importer applying for a foreign manufacturer needs a notarized Power of Attorney valid for at least five years, and proof of incorporation.[1] While, in Kenya, the Pharmacy and Poisons Board (PPB) accepts a licensed applicant who holds the registration certificate and is the main point of contact for complaints and vigilance.[2] [3]
But does appointing this representative mark the end of the manufacturer's involvement?
No. Maintaining technical documentation, managing risks, monitoring product performance and reporting safety concerns remain the manufacturer's responsibility throughout the device lifecycle.
Risk-based classification: not every device carries the same level of scrutiny
In the first instance, it is the manufacturer's own responsibility for self-classification of their product which determines how much scrutiny a device receives. This classification depends on device intended purpose, potential harm, invasiveness and duration of use,[4] and for IVDs, it’s dependent on the consequences of a wrong result and public-health risk.[5] A HIV blood-donor screening test, for example, sits in a higher class than a urine glucose strip.
Across the countries studied, most follow IMDRF's Class A to D; others, like Ethiopia, use Roman numerals I to IV for devices[6] while reserving A to D for IVDs.[7] These systems all separate lower from higher risk, but are not automatically interchangeable.
The registration journey: what happens after classification?
After classification, the applicant prepares the dossier and identifies the registration pathway. A core set of documents applies to almost every device: proof of local authorisation, evidence of a quality management system (usually ISO 13485), a declaration of conformity, a device description, labelling and instructions for use, and proof of approval in the country of origin.1,2,3 The evidence then grows with risk.
The pathway will then depend on how much of the assessment a trusted regulator has already done. In Kenya, a product with no reference-agency approval goes through full evaluation, while one approved by at least two reference agencies can use the abridged route for high-risk products. For example, Class B devices require approvals from at least two reference regulatory agencies, while Class C and D devices require at least three. The PPB also offers faster registration pathways for eligible devices with established regulatory approvals and a good market and safety record. Class B devices that qualify for this pathway can be registered immediately, with confirmation sent within 48 hours of submission. Separately, an emergency use pathway allows faster authorisation of products needed during public health emergencies, as happened during COVID-19.
So, when does the clock stop, and who stops it?
Is it the manufacturer? The local distributor? The regulator?
Some regulators publish processing timelines for evaluation — 120 workdays say for class A devices, or 240 workdays for the class B, C and D.1 But the clock doesn't belong to the regulator alone. The review clock runs while the file is with the regulator and stops when the file is with the applicant. The typical clock stoppers are a deficiency or query letter, a request for more clinical data, outstanding legalised documents, an inspection or sample test, and unpaid fees.
This means for the manufacturer, a clear regulatory strategy, realistic timelines and early preparation of technical dossiers is essential. For regulators, transparent procedures, predictable communication and efficient review systems to enable planning with greater confidence. Understanding when this clock starts, pauses and resumes is part of this planning.
Can reliance help move the process forward?
Reliance connects the registration pathway to a wider question: must every regulator repeat an assessment already conducted elsewhere?
A regulator can draw on the assessment or decision of another trusted authority while retaining responsibility for its own decision.[8] Our review identified reliance-related guidance or mechanisms in South Africa, Nigeria, Mozambique, Egypt and Botswana, although their scope and implementation differ.
For manufacturers, this reliance can reduce duplicated assessment work and potentially shorten review timelines. It, however, does not remove local submission requirements, and applicants must still prepare the supporting documentation required for the relevant pathway.
What does this mean for the journey ahead?
Having a regulatory framework is one step. Understanding how to navigate it is another. For manufacturers entering African markets, knowing the requirements, timelines and available pathways can make a difference in how they plan their market entry.
This is the foundation we are building at APN: interpreting the regulatory landscape across countries and translating it into practical market access strategies for industry.
REFERENCES
NAFDAC. Guidelines for Registration of Medical Devices Including In-Vitro Diagnostics (IVDs) and Related Products (VBM-R&RA-GDL-001-01).
https://nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/VBM_R&R/2025-2030/Guidelines-for-Registration-of-Medical-Devices-Including-In-Vitro-Diagnostics-IVDs-and-Related-Products.pdf ↑
MedDeviceGuide. Kenya PPB Medical Device Registration Guide https://meddeviceguide.com/blog/kenya-ppb-medical-device-registration-guide ↑
PPB. Guidelines for registration of medical devices Including In-Vitro diagnostics
https://web.pharmacyboardkenya.org/download/guidelines-for-registration-of-medical-devices-including-in-vitro diagnostics/?wpdmdl=6656&ind=1652079737220&refresh=0337c59b&filename=HPTPERHTPGUD011-Guideline-for-registration-of-MDs.pdf ↑
GHTF SG1/N77:2012. Principles of Medical Devices Classification. https://www.imdrf.org/sites/default/files/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n77-2012-principles-medical-devices-classification-121102.pdf ↑
GHTF SG1/N045:2008. Principles of In Vitro Diagnostic (IVD) Medical Devices Classification. https://www.imdrf.org/sites/default/files/docs/ghtf/final/sg1/procedural-docs/ghtf-sg1-n045-2008-principles-ivd-medical-devices-classification-080219.doc ↑
EEDA-GDL-041-Guideline-for-Classification-of-medical-Device-other-than-IVD-V1 https://www.efda.gov.et/wp-content/uploads/2026/07/EEDA-GDL-041-Guideline-for-Classification-of-medical-Device-other-than-IVD-V1.pdf ↑
EFDA-GDL-043-General Guidelines for Medical Devices Marketing Authorization https://www.efda.gov.et/wp-content/uploads/2026/07/EFDA-GDL-046-General-Guidelines-for-Medical-devices-Marketing-Authorization.pdf ↑
IMDRF Regulatory Reliance & Global Medical Device Harmonization: 2026 Guide | MedDeviceGuide https://meddeviceguide.com/blog/imdrf-regulatory-reliance-global-medical-device-harmonization-2026-guide ↑